S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:TECH

Bio-Techne Stock Forecast, Price & News

$367.10
-10.12 (-2.68%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$366.56
$379.68
50-Day Range
$367.10
$517.34
52-Week Range
$311.03
$543.85
Volume
399,498 shs
Average Volume
293,849 shs
Market Capitalization
$14.43 billion
P/E Ratio
84.78
Dividend Yield
0.34%
Beta
1.15
30 days | 90 days | 365 days | Advanced Chart
Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.


Bio-Techne logo

About Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The co

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
2,600
Year Founded
1981

Sales & Book Value

Annual Sales
$931.03 million
Cash Flow
$7.73 per share
Book Value
$40.40 per share

Profitability

Net Income
$140.41 million
Pretax Margin
17.90%

Debt

Price-To-Earnings

Miscellaneous

Free Float
37,684,000
Market Cap
$14.43 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/01/2021
Ex-Dividend for 11/26 Dividend
11/10/2021
Dividend Payable
11/26/2021
Today
1/23/2022
Next Earnings (Confirmed)
2/01/2022
Fiscal Year End
6/30/2022

Social Links


MarketRank

Overall MarketRank

2.75 out of 5 stars

Medical Sector

55th out of 1,419 stocks

Biological Products, Except Diagnostic Industry

7th out of 206 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

Is Bio-Techne a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bio-Techne stock.
View analyst ratings for Bio-Techne
or view top-rated stocks.

How has Bio-Techne's stock been impacted by COVID-19?

Bio-Techne's stock was trading at $180.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TECH shares have increased by 103.3% and is now trading at $367.10.
View which stocks have been most impacted by COVID-19
.

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for Bio-Techne
.

How can I listen to Bio-Techne's earnings call?

Bio-Techne will be holding an earnings conference call on Tuesday, February 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13726340".

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) announced its quarterly earnings results on Monday, November, 1st. The biotechnology company reported $1.83 earnings per share for the quarter, topping analysts' consensus estimates of $1.72 by $0.11. The biotechnology company had revenue of $257.72 million for the quarter, compared to analysts' expectations of $254.37 million. Bio-Techne had a trailing twelve-month return on equity of 15.86% and a net margin of 17.94%. During the same period last year, the firm posted $1.15 EPS.
View Bio-Techne's earnings history
.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Wednesday, November 3rd. Shareholders of record on Friday, November 12th will be paid a dividend of $0.32 per share on Friday, November 26th. This represents a $1.28 annualized dividend and a yield of 0.35%. The ex-dividend date is Wednesday, November 10th.
View Bio-Techne's dividend history
.

Is Bio-Techne a good dividend stock?

Bio-Techne pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.34%. The dividend payout ratio of Bio-Techne is 29.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 15.92% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.

What price target have analysts set for TECH?

8 brokers have issued 1-year target prices for Bio-Techne's shares. Their forecasts range from $400.00 to $548.00. On average, they expect Bio-Techne's stock price to reach $476.00 in the next year. This suggests a possible upside of 29.7% from the stock's current price.
View analysts' price targets for Bio-Techne
or view top-rated stocks among Wall Street analysts.

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the following people:

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne CEO Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among Bio-Techne's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a variety of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (0.60%), Conestoga Capital Advisors LLC (0.16%), Russell Investments Group Ltd. (0.11%), State of Alaska Department of Revenue (0.05%), Leavell Investment Management Inc. (0.05%) and Retirement Systems of Alabama (0.03%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne
.

Which major investors are selling Bio-Techne stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Crossmark Global Holdings Inc., Patton Fund Management Inc., Parallel Advisors LLC, Tributary Capital Management LLC, IBM Retirement Fund, Leavell Investment Management Inc., and Retirement Systems of Alabama. Company insiders that have sold Bio-Techne company stock in the last year include Brenda S Furlow, Charles R Kummeth, Glenn Hedde, James Hippel, Kim Kelderman, Norman David Eansor, and Roeland Nusse.
View insider buying and selling activity for Bio-Techne
or view top insider-selling stocks.

Which major investors are buying Bio-Techne stock?

TECH stock was purchased by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Segantii Capital Management Ltd, Royal London Asset Management Ltd., Russell Investments Group Ltd., State of Alaska Department of Revenue, Wealthfront Advisers LLC, Radnor Capital Management LLC, and Agate Pass Investment Management LLC.
View insider buying and selling activity for Bio-Techne
or or view top insider-buying stocks.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $367.10.

How much money does Bio-Techne make?

Bio-Techne has a market capitalization of $14.43 billion and generates $931.03 million in revenue each year. The biotechnology company earns $140.41 million in net income (profit) each year or $4.33 on an earnings per share basis.

How many employees does Bio-Techne have?

Bio-Techne employs 2,600 workers across the globe.

Does Bio-Techne have any subsidiaries?

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.

When was Bio-Techne founded?

Bio-Techne was founded in 1981.

What is Bio-Techne's official website?

The official website for Bio-Techne is www.bio-techne.com.

Where are Bio-Techne's headquarters?

Bio-Techne is headquartered at 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at (612) 379-8854, via email at [email protected], or via fax at 612-656-4400.


This page was last updated on 1/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.